Torsten Gerriet Blum

Dr. Torsten Gerriet Blum

Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
TBTorsten Gerriet Blum
Torsten Gerriet Blum
DMDaniel Misch
Daniel Misch
JKJens Kollmeier
Jens Kollmeier
STSebastian Thiel
Sebastian Thiel
TBTorsten T. Bauer
Torsten T. Bauer
Thymomas are counted among the rare tumour entities which are associated with autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other malignancies. Through its complex immunological function in the context of the selection and maturation of T cells, the thymus is at the same time highly susceptible to disruptive factors caused by the development and growth of thymic tumours. These T cells, which are thought to develop to competent immune cells in the thymus, can instead adopt autoreactive behaviour due to the uncontrolled interplay of thymomas and become the trigger for AID or PNS affecting numerous organs and tissues within the human body. While myasthenia gravis is the most prevalent PNS in thymoma, numerous others have been described, be they related to neurological, cardiovascular, gastrointestinal, haematological, dermatological, endocrine or systemic disorders. This review article sheds light on the pathophysiology, epidemiology, specific clinical features and therapeutic options of the various forms as well as courses and outcomes of AID/PNS in association with thymomas. Whenever suitable and backed by the limited available evidence, the perspectives from both the thymoma and the affected organ/tissue will be highlighted. Specific issues addressed are the prognostic significance of thymectomy on myasthenia gravis and other thymoma-associated AID/PND and further the impact and safety of immunotherapies on AID and PND relating to thymomas.

Verified
Journal Article
Open access
PDF file
SSSusann Stephan-Falkenau
Susann Stephan-Falkenau
ASAnna Streubel
Anna Streubel
TMThomas Mairinger
Thomas Mairinger
TBTorsten Gerriet Blum
Torsten Gerriet Blum
JKJens Kollmeier
Jens Kollmeier
MWMichael Wessolly
Michael Wessolly
Pulmonary sarcomatoid carcinoma (PSC) has highly aggressive biological behaviour and poor clinical outcomes, raising expectations for new therapeutic strategies. We characterized 179 PSC by immunohistochemistry, next-generation sequencing and in silico analysis using a deep learning algorithm with respect to clinical, immunological and molecular features. PSC was more common in men, older ages and smokers. Surgery was an independent factor (p < 0.01) of overall survival (OS). PD-L1 expression was detected in 82.1% of all patients. PSC patients displaying altered epitopes due to processing mutations showed another PD-L1-independent immune escape mechanism, which also significantly influenced OS (p < 0.02). The effect was also maintained when only advanced tumour stages were considered (p < 0.01). These patients also showed improved survival with a significant correlation for immunotherapy (p < 0.05) when few or no processing mutations were detected, although this should be interpreted with caution due to the small number of patients studied. Genomic alterations for which there are already approved drugs were present in 35.4% of patients. Met exon 14 skipping was found more frequently (13.7%) and EGFR mutations less frequently (1.7%) than in other NSCLC. In summary, in addition to the divergent genomic landscape of PSC, the specific immunological features of this prognostically poor subtype should be considered in therapy stratification.

10 October 2023 in Pneumologie
Verified
Journal Article
Closed access
PDF file
TBTorsten Gerriet Blum
Torsten Gerriet Blum
JVJens Vogel-Claussen
Jens Vogel-Claussen
SAStefan Andreas
Stefan Andreas
TBTorsten T. Bauer
Torsten T. Bauer
JBJoerg Barkhausen
Joerg Barkhausen
HHHans Hoffmann
Hans Hoffmann
Der Prozess zur Implementierung der Lungenkrebsfrüherkennung mit Niedrigdosis-CT (LDCT) in Deutschland hat in den letzten Jahren deutlich an Dynamik gewonnen. Es wird erwartet, dass der von den Fachgesellschaften kommentierte Referentenentwurf des Bundesministeriums für Umwelt, Naturschutz, nukleare Sicherheit und Verbraucherschutz (BMUV) zur Lungenkrebsfrüherkennung noch bis Ende 2023 in Kraft tritt. Basierend auf dieser Verordnung wird der Gemeinsame Bundesausschuss (G-BA) zeitnah ein Programm zur Lungenkrebsfrüherkennung mit LDCT aufsetzten. In diesem Positionspapier stellen die im Lungenkrebsscreening beteiligten Fachgesellschaften erstmals konkrete Eckpunkte für ein einheitliches, strukturiertes und qualitätsgesichertes Früherkennungsprogramm für Lungenkrebs in Deutschland vor, um zu diesem Prozess konstruktiv beizutragen. The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process. * geteilte Erstautorenschaft ** geteilte Letztautorenschaft Article published online: 10 October 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Verified
Journal Article
Open access
PDF file
SSSusann Stephan-Falkenau
Susann Stephan-Falkenau
ASAnna Streubel
Anna Streubel
TMThomas Mairinger
Thomas Mairinger
JKJens Kollmeier
Jens Kollmeier
DMDaniel Misch
Daniel Misch
TBTorsten Gerriet Blum
Torsten Gerriet Blum
Precision oncology and immunotherapy have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also beneficial for patients with driver alterations such as epidermal growth factor receptor (EGFR) mutations in early-stage NSCLC (stages I–IIIA). Furthermore, patients with elevated programmed death-ligand 1 (PD-L1) expression appear to respond favorably to adjuvant immunotherapy. To determine the frequency of genomic alterations and PD-L1 status in early-stage NSCLC, we retrospectively analyzed data from 2066 unselected, single-center patients with NSCLC diagnosed using next-generation sequencing and immunohistochemistry. Nine-hundred and sixty-two patients (46.9%) presented with early-stage NSCLC. Of these, 37.0% had genomic alterations for which targeted therapies have already been approved for advanced NSCLC. The frequencies of driver mutations in the early stages were equivalent to those in advanced stages, i.e., the rates of EGFR mutations in adenocarcinomas were 12.7% (72/567) and 12.0% (78/650) in early and advanced NSCLC, respectively (p = 0778). In addition, 46.3% of early-stage NSCLC cases were PD-L1-positive, with a tumor proportion score (TPS) of ≥1%. With comparable frequencies of driver mutations in early and advanced NSCLC and PD-L1 overexpression in nearly half of patients with early-stage NSCLC, a broad spectrum of biomarkers for adjuvant and neoadjuvant therapies is available, and several are currently being investigated in clinical trials.

10 October 2023 in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
Verified
Journal Article
Closed access
PDF file
JVJens Vogel-Claussen
Jens Vogel-Claussen
TBTorsten Gerriet Blum
Torsten Gerriet Blum
SAStefan Andreas
Stefan Andreas
TBTorsten T. Bauer
Torsten T. Bauer
JBJörg Barkhausen
Jörg Barkhausen
DTDeutsche Gesellschaft Für Thoraxchirurgie
Deutsche Gesellschaft Für Thoraxchirurgie
Der Prozess zur Implementierung der Lungenkrebsfrüherkennung mit Niedrigdosis-CT (LDCT) in Deutschland hat in den letzten Jahren deutlich an Dynamik gewonnen. Es wird erwartet, dass der von den Fachgesellschaften kommentierte Referentenentwurf des Bundesministeriums für Umwelt, Naturschutz, nukleare Sicherheit und Verbraucherschutz (BMUV) zur Lungenkrebsfrüherkennung noch bis Ende 2023 in Kraft tritt. Basierend auf dieser Verordnung wird der Gemeinsame Bundesausschuss (G-BA) zeitnah ein Programm zur Lungenkrebsfrüherkennung mit LDCT aufsetzten. In diesem Positionspapier stellen die im Lungenkrebsscreening beteiligten Fachgesellschaften erstmals konkrete Eckpunkte für ein einheitliches, strukturiertes und qualitätsgesichertes Früherkennungsprogramm für Lungenkrebs in Deutschland vor, um zu diesem Prozess konstruktiv beizutragen. The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on the early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present key points for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process. Citation Format * geteilte Erstautorenschaft ** geteilte Letztautorenschaft Article published online: 10 October 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

10 October 2023 in Zentralblatt fur Chirurgie
Verified
Journal Article
Closed access
PDF file
HHHans Hoffmann
Hans Hoffmann
RKRudolf Kaaks
Rudolf Kaaks
SAStefan Andreas
Stefan Andreas
TBTorsten T. Bauer
Torsten T. Bauer
JBJoerg Barkhausen
Joerg Barkhausen
TBTorsten Gerriet Blum
Torsten Gerriet Blum
Der Prozess zur Implementierung der Lungenkrebsfrüherkennung mit Niedrigdosis-CT (LDCT) in Deutschland hat in den letzten Jahren deutlich an Dynamik gewonnen. Es wird erwartet, dass der von den Fachgesellschaften kommentierte Referentenentwurf des Bundesministeriums für Umwelt, Naturschutz, nukleare Sicherheit und Verbraucherschutz (BMUV) zur Lungenkrebsfrüherkennung noch bis Ende 2023 in Kraft tritt. Basierend auf dieser Verordnung wird der Gemeinsame Bundesausschuss (G-BA) zeitnah ein Programm zur Lungenkrebsfrüherkennung mit LDCT aufsetzten. In diesem Positionspapier stellen die im Lungenkrebs-Screening beteiligten Fachgesellschaften erstmals konkrete Eckpunkte für ein einheitliches, strukturiertes und qualitätsgesichertes Früherkennungsprogramm für Lungenkrebs in Deutschland vor, um zu diesem Prozess konstruktiv beizutragen. The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process. * geteilte Erstautorenschaft ** geteilte Letztautorenschaft Article published online: 10 October 2023 Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany